References
- Akashi YJ, Ishihara M. Takotsubo syndrome: insights from Japan. Heart Fail Clin. 2016;12(4):587–595.
- Di Filippo C, Bacchi B, Di Mario C. Novel aspects of classification, prognosis and therapy in takotsubo syndrome. Eur Cardiol. 2019;14(3):191–196.
- Templin C, Ghadri JR, Diekmann J, et al. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373(10):929–938.
- Kido K, Guglin M. Drug-Induced takotsubo cardiomyopathy. J Cardiovasc Pharmacol Ther. 2017;22(6):552–563.
- Bodziock G, Armstrong C, Montgomery J. Flecainide overdose presenting with long QT and acute takotsubo cardiomyopathy. J Electrocardiol. 2019;52:7–9.
- Medina de Chazal H, Del Buono MG, Keyser-Marcus L, et al. Stress cardiomyopathy diagnosis and Treatment: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018;72(16):1955–1971.
- Aweimer A, El-Battrawy I, Akin I, et al. Abnormal thyroid function is common in takotsubo syndrome and depends on two distinct mechanisms: results of a multicentre observational study. J Intern Med. 2021;289(5):675–687.
- Gabriel L, Chenu P, Guédès A, et al. A possible association between takotsubo cardiomyopathy and treatment with flecainide. Int J Cardiol. 2011;147(1):173–175.
- Brugada J, Katritsis DG, Arbelo E, et al. ESC Scientific Document Group. 2019 ESC guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC)). Eur Heart J. 2020;41(5):655–720. Feb 1. https://doi.org/10.1093/eurheartj/ehz467.